Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Amyloid Fibrils

Amyloid Fibrils

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CGRP-Targeting Therapies in Vestibular Migraine: A Synthesis of Observational Evidence with Direction-of-Effect Analysis.

Medical sciences (Basel, Switzerland)·2026

Same author

Alpha-Lipoic Acid and Benfotiamine in Diabetic Peripheral Neuropathy: A Critical Review of Mechanistic Rationale and Clinical Evidence Within a Nutritional Therapeutic Framework.

Nutrients·2026

Same author

Modeling of Polyolefin-Aluminum Bonding Technology Under Electromagnetic Energy: Using Hot-Melt Adhesives with Metallic Micro-Additives.

Polymers·2026

Same author

Composites from Recycled Polyolefin and Waste Plant Biomass with Potential Uses in Electrical Insulation Applications.

Materials (Basel, Switzerland)·2026

Same author

Clinical Prediction of Functional Decline in Multiple Sclerosis Using Volumetry-Based Synthetic Brain Networks.

Life (Basel, Switzerland)·2026

Same author

Neurological Complications in Children with Moyamoya Disease-Case Report and Literature Review.

Journal of clinical medicine·2026

Search research articles

Related Experiment Video

Updated: Mar 29, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

Tau Protein Aggregation Inhibitors-Therapeutic Strategy for Concurrent Tau and Amyloid Aggregation Inhibition.

Thomas Gabriel Schreiner^1,2, Romeo Cristian Ciobanu³, Oliver Daniel Schreiner^1,4

¹Department of Medical Specialties III, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.

|March 28, 2026

Summary

This review explores tau protein aggregation inhibitors for neurodegenerative diseases like Alzheimer's. It highlights current drugs and novel compounds targeting both tau and amyloid-β pathologies for future therapies.

Keywords:

Alzheimer’s disease curcumin neurodegeneration small-molecule inhibitor tau protein

More Related Videos

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Related Experiment Videos

Last Updated: Mar 29, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Area of Science:

Neuroscience
Pharmacology
Biochemistry

Background:

Tau protein aggregation into neurofibrillary tangles is central to neurodegenerative diseases, notably Alzheimer's disease.
Pathological tau disrupts neuronal function, promoting neuroinflammation and amyloid plaque formation, ultimately causing cell death.
Inhibiting tau aggregation is a critical therapeutic strategy for these debilitating conditions.

Purpose of the Study:

To provide a practical overview of current tau protein aggregation inhibitors.
To discuss emerging compounds with dual activity against tau and amyloid-β pathology.
To offer a forward-looking framework for developing next-generation disease-modifying therapies.

Main Methods:

Systematic analysis of recent preclinical and clinical evidence on tau aggregation inhibitors.
Review of small-molecule inhibitors and natural compounds targeting tau pathology.
Emphasis on compounds with dual activity against tau and amyloid-β.

Main Results:

Established classes of tau aggregation inhibitors are presented with examples from clinical trials.
Emerging compounds with dual tau and amyloid-β inhibitory activity are highlighted.
Mechanistic convergence, repurposing opportunities, and therapeutic combinations are discussed.

Conclusions:

Tau aggregation inhibitors represent a key research direction for neurodegenerative diseases.
Dual-acting compounds offer promising therapeutic potential for multifactorial diseases.
This review identifies promising candidates for future disease-modifying therapies.